Harmony Biosciences Holdings (HRMY) Depreciation & Amortization (CF) (2019 - 2026)

Harmony Biosciences Holdings has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $7000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $7000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $20000.0 (down 81.98% YoY), and the FY2024 annual result was $267000.0, down 48.05% from the prior year.
• Depreciation & Amortization (CF) came in at $7000.0 for Q1 2026 at Harmony Biosciences Holdings, roughly flat from $7000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $164000.0 in Q4 2023 to a low of $6000.0 in Q4 2024.
• The 5-year median for Depreciation & Amortization (CF) is $97500.0 (2022), against an average of $76687.5.
• Peak annual rise in Depreciation & Amortization (CF) reached 58.25% in 2024, while the deepest fall reached 96.34% in 2024.
• Harmony Biosciences Holdings' Depreciation & Amortization (CF) stood at $107000.0 in 2022, then soared by 53.27% to $164000.0 in 2023, then tumbled by 96.34% to $6000.0 in 2024, then grew by 16.67% to $7000.0 in 2025, then changed by 0.0% to $7000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $7000.0 (Q1 2026), $7000.0 (Q3 2025), and $6000.0 (Q2 2025), per Business Quant data.